NAD+ vs "Glow" Blend: What the Research Compares

Nicotinamide adenine dinucleotide (NAD+) is a pyridine dinucleotide coenzyme, also referred to in the literature as diphosphopyridine nucleotide (DPN) and coenzyme I. It is composed of two nucleotides joined through their phosphate groups, an adenine nucleotide and a nicotinamide nucleotide, and it functions as an electron carrier in oxidoreduction reactions. The "Glow" blend is a research material supplied under the catalogue designation Glow blend 70mg; the evidence block provided for this comparison does not give a sequence, formula, molecular weight, or other identifier for it, and no published study in the evidence block names it as a test article.

The published work relevant to this comparison centres on nicotinamide (vitamin B3), the amide form of niacin and a precursor in the NAD+ salvage pathway, and on light-based protocols that are described in terms of skin appearance rather than a defined receptor family.

Research Studies

Nicotinamide and retinal nerve cell layer thinning in primary open-angle glaucoma

The NADIR trial is a clinical study designed to learn whether high-dose nicotinamide can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment [1]. The main question it aims to answer is whether adding nicotinamide to standard glaucoma therapy slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared with standard therapy alone over 12 months [1]. Participants are randomly assigned to one of two groups; those in the treatment group take nicotinamide tablets by mouth, starting at a lower dose of 1.5 grams per day [1].

Nicotinamide and tryptophan metabolism in post-COVID syndrome

In patients with post-COVID syndrome, changes in tryptophan metabolism, energy metabolism, and the gut microbiome may occur [2]. In an earlier nutritional study, patients with COVID-19 recovered their physical performance more quickly when taking nicotinamide, and patients who responded to nicotinamide also developed post-COVID syndrome less frequently [2]. At the University Hospital Schleswig-Holstein in Kiel, special nicotinamide tablets (CICR-NAM) were developed that release the active substance selectively in the lower intestine and have been shown to be very well tolerated in several studies [2]. Patients with post-COVID syndrome and documented tryptophan deficiency may therefore take one [2].

Perineural dextrose and perineural local anesthetic in knee osteoarthritis

A prospective observational study aims to compare the clinical effectiveness of perineural 5% dextrose injections and perineural local anesthetic injections in patients with symptomatic knee osteoarthritis [3]. Adult patients receiving routine perineural injection therapy are followed for six months, with pain intensity and functional outcomes assessed at baseline and at 1, 3, and 6 months after treatment using validated clinical assessment tools [3]. This study does not name NAD+ or the "Glow" blend as an intervention.

Blue, red, and infrared light exposure and skin appearance

A light therapy protocol described in the evidence block delivers twice-weekly sessions that blend blue, red, and infrared light [5]. Each 20-minute session flows through three phases: blue light first, then red light, then infrared light, and the protocol is described as being designed to help unlock healthier-looking skin and boost natural glow [5]. The evidence block does not identify a molecular target, a measured biomarker, or a comparator arm for this protocol.

Maridebart cafraglutide and cardiovascular outcomes in atherosclerotic cardiovascular disease with overweight or obesity

A trial's primary objective is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular morbidity and mortality in participants with atherosclerotic cardiovascular disease and overweight or obesity [6]. This agent is not NAD+ and is not the "Glow" blend; it is included here only because it appears in the same evidence set.

Afimkibart (RO7790121) induction therapy in Crohn's disease

A Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with afimkibart, also known as RO7790121, in participants with moderately to severely active Crohn's disease [7]. As with maridebart cafraglutide, this is a distinct agent and does not bear on the NAD+ versus "Glow" blend question.

Debrisoft Duo and Debrisoft Pad in wound debridement

A post-market clinical follow-up study aims to confirm the performance of Debrisoft Duo, to collect safety data regarding expected adverse events, and to detect potential unexpected adverse events associated with its use within the certified indications and under the conditions of routine use, comparing it with the Debrisoft Pad in the debridement of wounds [8]. This is a device comparison and does not involve either compound under discussion.

Guizhi Wuling Decoction and mitochondrial homeostasis in myocardial fibrosis

Guizhi Wuling Decoction (GWD), a combined prescription consisting of the classical formulas Wuling San and Guizhi Fuling Wan without modification, has been clinically applied for cardiovascular diseases, and previous studies have reported its cardioprotective and anti-fibrotic effects [9]. The work reports that GWD alleviates myocardial fibrosis by restoring mitochondrial homeostasis, drawing on network pharmacology, molecular docking, and multi-omics integration [9]. This is a botanical formula and is not NAD+ or the "Glow" blend.

Barriers to care for urinary incontinence and prolapse in global majority women

A project aims to explore barriers to treatment seeking for symptoms of prolapse and urinary incontinence in women from ethnic minority and global majority backgrounds [4]. It collects objective data using validated questionnaires, including the Prolapse and Incontinence Knowledge Questionnaire (PIKQ), the Female Genital Self-Image Scale (FGSIS-4), and measures of prevalence and severity of urinary incontinence and pelvic organ prolapse (ICIQ-UI Short Form and ICIQ-VS), alongside age, level of education, level of deprivation according to postcode, faith, first or preferred language spoken, sexual orientation, and employment status [4]. This study does not involve either compound.

What the two subjects are, side by side

Where the evidence is stronger

For nicotinamide, the evidence block contains two registered clinical studies with defined populations, defined interventions, and defined outcome measures: adults with primary open-angle glaucoma already on standard therapy, with inner retinal nerve cell layer thinning measured by a non-invasive eye scan over 12 months [1], and patients with post-COVID syndrome and documented tryptophan deficiency, with a lower-intestine-release tablet formulation [2]. Both are prospective and both specify a population. For the "Glow" blend, the evidence block contains no study that names it, no population, no outcome measure, and no comparator. On the material available here, the published work is stronger for nicotinamide, and it is absent for the "Glow" blend.

What is simply not known

• No sequence, formula, or molecular weight is given for either NAD+ or the "Glow" blend in the evidence block.
• No study in the evidence block administers NAD+ itself as a test article; the clinical work concerns nicotinamide, a precursor.
• No study in the evidence block names the "Glow" blend, so no effect, in any population, can be attributed to it from this material.
• The light protocol described in the evidence block reports no molecular target and no measured biomarker [5].
• No head-to-head study of NAD+ and the "Glow" blend appears in the evidence block.
• Several studies in the evidence block concern unrelated agents and devices and cannot be used to support any claim about either compound [3][4][6][7][8][9].

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for any person to take any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
• [2] Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS) — https://clinicaltrials.gov/study/NCT07798570
• [3] Perineural Dextrose Versus Local Anesthetic Injections in Knee Osteoarthritis — https://clinicaltrials.gov/study/NCT07381621
• [4] Barriers and Enablers to Accessing Medical Care for Urinary Incontinence and Prolapse in GLobal Majority Women — https://clinicaltrials.gov/study/NCT07310121
• [5] See the Impact Beem's Blue Light Therapy Has on Your Skin Health! — https://clinicaltrials.gov/study/NCT07298382
• [6] Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — https://clinicaltrials.gov/study/NCT07037433
• [7] A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — https://clinicaltrials.gov/study/NCT06819891
• [8] Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft Duo With Debrisoft Pad in the Debridement of Wounds — https://clinicaltrials.gov/study/NCT07312513
• [9] Guizhi Wuling Decoction alleviates myocardial fibrosis by restoring mitochondrial homeostasis: Evidence from network pharmacology, molecular docking, and multi-omics integration. — https://pubmed.ncbi.nlm.nih.gov/42462419/